Online behavioral intervention increases physical activity and improves depression in newly diagnosed multiple sclerosis
Can online coaching help people newly diagnosed with MS get moving and feel better?
A pilot randomized controlled trial in 50 people newly diagnosed with MS found that a 16-week COM-B-based online behavioral intervention sig…
Online coaching helped newly diagnosed MS patients add 11 minutes of daily activity, feel less depressed, and improve mental health quality …
FDA Approves Kesimpta (ofatumumab) for Relapsing Forms of Multiple Sclerosis in Adults
The FDA approved a new monthly self-injection drug for multiple sclerosis
The FDA has approved Kesimpta, a CD20-directed cytolytic antibody, for the treatment of relapsing forms of multiple sclerosis in adults.
The FDA approved Kesimpta, a new monthly self-injection for adults with relapsing forms of multiple sclerosis.
Neuromuscular electrostimulation plus swallowing therapy may benefit dysphagia in severely disabled MS patients
Can electrical stimulation help people with MS swallow more easily?
A randomized controlled trial in 101 people with MS and dysphagia found both traditional swallowing therapy plus neuromuscular electrostimul…
For people with advanced multiple sclerosis, adding gentle electrical stimulation to standard swallowing therapy led to significantly greate…
Percutaneous balloon compression shows initial pain relief in multiple sclerosis-related trigeminal neuralgia
Balloon compression procedure shows initial pain relief for MS-related facial pain
A systematic review and meta-analysis of 12 studies involving 386 patients with MS-related trigeminal neuralgia found percutaneous balloon c…
A balloon compression procedure offers immediate pain relief for most people with severe facial pain caused by multiple sclerosis, though lo…
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years
Could Ponesimod Change the Game for Multiple Sclerosis Patients?
In a 5-year extension of the OPTIMUM study, ponesimod 20 mg maintained a lower ARR (0.143) compared to teriflunomide switchers (0.184).
After five years, nearly half of people taking ponesimod for multiple sclerosis had no relapses, offering more stable lives with fewer unexp…